Telix Pharmaceuticals Management
Management criteria checks 4/4
Telix Pharmaceuticals' CEO is Chris Behrenbruch, appointed in Jul 2023, has a tenure of 1.33 years. total yearly compensation is A$1.02M, comprised of 49% salary and 51% bonuses, including company stock and options. directly owns 6.94% of the company’s shares, worth $349.24M. The average tenure of the management team and the board of directors is 2.2 years and 7.2 years respectively.
Key information
Chris Behrenbruch
Chief executive officer
AU$1.0m
Total compensation
| CEO salary percentage | 49.0% |
| CEO tenure | 1.3yrs |
| CEO ownership | 6.9% |
| Management average tenure | 2.2yrs |
| Board average tenure | 7.2yrs |
Recent management updates
No updates
Recent updates
No updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | AU$49m |
| Mar 31 2024 | n/a | n/a | AU$32m |
| Dec 31 2023 | AU$1m | AU$499k | AU$5m |
| Sep 30 2023 | n/a | n/a | -AU$21m |
| Jun 30 2023 | n/a | n/a | -AU$48m |
| Mar 31 2023 | n/a | n/a | -AU$77m |
| Dec 31 2022 | AU$865k | AU$422k | -AU$104m |
| Sep 30 2022 | n/a | n/a | -AU$111m |
| Jun 30 2022 | n/a | n/a | -AU$119m |
| Mar 31 2022 | n/a | n/a | -AU$100m |
| Dec 31 2021 | AU$620k | AU$374k | -AU$81m |
| Sep 30 2021 | n/a | n/a | -AU$70m |
| Jun 30 2021 | n/a | n/a | -AU$59m |
| Mar 31 2021 | n/a | n/a | -AU$52m |
| Dec 31 2020 | AU$421k | AU$295k | -AU$45m |
| Sep 30 2020 | n/a | n/a | -AU$40m |
| Jun 30 2020 | n/a | n/a | -AU$36m |
| Mar 31 2020 | n/a | n/a | -AU$32m |
| Dec 31 2019 | AU$460k | AU$317k | -AU$28m |
| Sep 30 2019 | n/a | n/a | -AU$23m |
| Jun 30 2019 | n/a | n/a | -AU$19m |
| Mar 31 2019 | n/a | n/a | -AU$16m |
| Dec 31 2018 | AU$380k | AU$280k | -AU$14m |
| Sep 30 2018 | n/a | n/a | -AU$12m |
| Jun 30 2018 | n/a | n/a | -AU$10m |
| Mar 31 2018 | n/a | n/a | -AU$8m |
| Dec 31 2017 | AU$303k | AU$211k | -AU$6m |
Compensation vs Market: Chris's total compensation ($USD665.18K) is below average for companies of similar size in the US market ($USD7.97M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Behrenbruch (48 yo)
1.3yrs
Tenure
AU$1,018,461
Compensation
Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharm...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 1.3yrs | AU$1.02m | 6.94% $ 349.2m | |
| Group Chief Financial Officer | 2.3yrs | AU$713.90k | 0.0019% $ 97.6k | |
| Chief Medical Advisor | no data | AU$43.00k | 6.78% $ 340.9m | |
| Group Chief Medical Officer | less than a year | no data | 0.11% $ 5.6m | |
| Chief Executive Officer of Telix Therapeutics | 3.5yrs | AU$902.90k | 0.060% $ 3.0m | |
| Group Chief Operating Officer | less than a year | no data | 0% $ 0 | |
| Chief Scientist | 3.5yrs | AU$167.76k | no data | |
| Chief Information Officer | 1.8yrs | no data | no data | |
| Senior Vice President of Corporate Communications & Investor Relations | 3.3yrs | no data | no data | |
| Group General Counsel | 2.2yrs | no data | no data | |
| Vice President of Sales | no data | no data | no data | |
| Senior Vice President of Global People & Culture | 2.2yrs | no data | no data |
2.2yrs
Average Tenure
53.5yo
Average Age
Experienced Management: TLX's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.8yrs | AU$1.02m | 6.94% $ 349.2m | |
| Independent Non-Executive Chairman | 7.2yrs | AU$188.28k | 0.34% $ 17.3m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 7.2yrs | AU$103.30k | 1.08% $ 54.6m | |
| Independent Non-Executive Director | 6.4yrs | AU$111.56k | 0.18% $ 8.9m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data |
7.2yrs
Average Tenure
65yo
Average Age
Experienced Board: TLX's board of directors are considered experienced (7.2 years average tenure).